OrthoTrophix to present TPX-100 data at OARSI

OrthoTrophix will present data on long-term clinical benefit of TPX-100 in mild to severe knee osteoarthritis patients at OARSI annual meeting

DDNews Staff
Register for free to listen to this article
Listen with Speechify
0:00
5:00
OAKLAND, Calif.—OrthoTrophix, Inc., a privately held biopharmaceutical company, has announced that the company plans to report long-term clinical benefits in mild to severe knee osteoarthritis (OA) patients who were treated with TPX-100 at the 2018 OARSI annual meeting, held this year in Liverpool, U.K., from April 26 - 29.
 
OrthoTrophix previously presented the results of a Phase 2 clinical study in which the company’s OA drug candidate, TPX-100 improved knee function and physical quality of life at 6 and 12 months after treatment, compared with placebo. A follow-on protocol, TPX-100-4, assessed the same patient reported outcomes in subjects who participated in TPX-100-1.
 
The average time from the initial TPX-100 treatment was 30 months, with a range of 28 - 35 months. Exclusion criteria included knee surgery or investigational drugs for OA in the interim between TPX-100-1 and TPX-100-4. Of the 93 subjects in TPX-100-1, 53 enrolled in TPX-100-4. Topline results of this follow-on study will be included in the poster session of the 2018 OARSI annual meeting under the abstract entitled “TPX-100 Leads To Marked, Sustained Improvements In Subjects With Knee Osteoarthrits.”
 
The company’s Chief Medical Officer, Dawn McGuire, M.D., FAAN said, “The long-term follow-on study enrolled over half the TPX-100-1 subjects, despite being an observational study only. The sustained improvement in knee function for more than two years in knees injected with TPX-100 confirms our confidence in TPX-100 as a drug with the potential to modify the disease of knee osteoarthritis as patients actually experience it.”

DDNews Staff

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue